

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/233764 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/EP2022/061661

(22) International Filing Date:
02 May 2022 (02.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/183,280 03 May 2021 (03.05.2021) US

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; 60, Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: **LIGHTWOOD, Daniel John**; c/o IPD, UCB, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **KADIU, Irena**; c/o IPD, UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE). **BHATTA, Pallavi**; c/o IPD, UCB, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **SPILIOTOPOULOS, Anastasios**; c/o IPD, UCB, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **EL-LIOTT, Peter Charles**; c/o IPD, UCB, 208 Bath Road, Slough, Berkshire SL 1 3WE (GB). **KEANEY, James Martin**; c/o IPD, UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE). **DELKER, Silvia L.**; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE). **ABENDROTH, Jan**; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; c/o UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: ANTIBODIES

(57) Abstract: The present invention relates to antibodies binding to TREM1 and inhibiting its interaction with one or more of its natural ligands. Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such are also provided.



WO 2022/233764 A1